Year |
Citation |
Score |
2023 |
Caswell DR, Gui P, Mayekar MK, Law EK, Pich O, Bailey C, Boumelha J, Kerr DL, Blakely CM, Manabe T, Martinez-Ruiz C, Bakker B, De Dios Palomino Villcas J, I Vokes N, Dietzen M, ... ... Gini B, et al. The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance. Nature Genetics. PMID 38049664 DOI: 10.1038/s41588-023-01592-8 |
0.383 |
|
2020 |
Gini B, Thomas N, Blakely CM. Impact of concurrent genomic alterations in epidermal growth factor receptor ()-mutated lung cancer. Journal of Thoracic Disease. 12: 2883-2895. PMID 32642201 DOI: 10.21037/Jtd.2020.03.78 |
0.496 |
|
2017 |
Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nature Genetics. PMID 29106415 DOI: 10.1038/Ng.3990 |
0.459 |
|
2017 |
Gu Y, Albuquerque CP, Braas D, Zhang W, Villa GR, Bi J, Ikegami S, Masui K, Gini B, Yang H, Gahman TC, Shiau AK, Cloughesy TF, Christofk HR, Zhou H, et al. mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT. Molecular Cell. PMID 28648777 DOI: 10.1016/J.Molcel.2017.05.030 |
0.679 |
|
2016 |
Okimoto RA, Breitenbuecher F, Olivas VR, Wu W, Gini B, Hofree M, Asthana S, Hrustanovic G, Flanagan J, Tulpule A, Blakely CM, Haringsma HJ, Simmons AD, Gowen K, Suh J, et al. Inactivation of Capicua drives cancer metastasis. Nature Genetics. PMID 27869830 DOI: 10.1038/Ng.3728 |
0.359 |
|
2016 |
Wei W, Shin YS, Xue M, Matsutani T, Masui K, Yang H, Ikegami S, Gu Y, Herrmann K, Johnson D, Ding X, Hwang K, Kim J, Zhou J, Su Y, ... ... Gini B, et al. Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Cancer Cell. 29: 563-73. PMID 27070703 DOI: 10.1016/J.Ccell.2016.03.012 |
0.738 |
|
2015 |
Tanaka K, Sasayama T, Irino Y, Takata K, Nagashima H, Satoh N, Kyotani K, Mizowaki T, Imahori T, Ejima Y, Masui K, Gini B, Yang H, Hosoda K, Sasaki R, et al. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. The Journal of Clinical Investigation. 125: 1591-602. PMID 25798620 DOI: 10.1172/Jci78239 |
0.743 |
|
2015 |
Shin YS, Wei W, Gini B, Mischel P, Heath J. Abstract PR09: Single cell phosphoproteomics identifies adaptive network dynamics of mTOR inhibitor resistance and defines effective combination therapy in glioblastoma Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-Pr09 |
0.653 |
|
2014 |
Gini B, Mischel PS. Greater than the sum of its parts: single-nucleus sequencing identifies convergent evolution of independent EGFR mutants in GBM. Cancer Discovery. 4: 876-8. PMID 25092745 DOI: 10.1158/2159-8290.Cd-14-0635 |
0.577 |
|
2014 |
Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science (New York, N.Y.). 343: 72-6. PMID 24310612 DOI: 10.1126/Science.1241328 |
0.704 |
|
2014 |
Tanaka K, Sasayama T, Irino Y, Takata K, Nagashima H, Masui K, Gini B, Yang H, Mischel PS, Kohmura E. NT-39 * GLUTAMINASE-MEDIATED METABOLIC PATHWAY INVOLVES GLIOBLASTOMA RESISTANCE TO mTOR-TARGETED THERAPIES Neuro-Oncology. 16: v167-v167. DOI: 10.1093/Neuonc/Nou265.37 |
0.698 |
|
2014 |
Gini B, Bonetti B, Mischel P. Hypoxia Regulation of Sensitivity to the Mechanistic Target of Rapamycin Kinase Inhibition (Mtorki) in Glioblastoma Multiforme Annals of Oncology. 25: iv571. DOI: 10.1093/Annonc/Mdu359.28 |
0.622 |
|
2013 |
Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, Iwanami A, Liu F, Villa GR, Gu Y, Campos C, Zhu S, Yang H, Yong WH, Cloughesy TF, et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metabolism. 18: 726-39. PMID 24140020 DOI: 10.1016/J.Cmet.2013.09.013 |
0.69 |
|
2013 |
Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, et al. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5722-32. PMID 24030701 DOI: 10.1158/1078-0432.Ccr-13-0527 |
0.741 |
|
2013 |
Babic I, Anderson ES, Tanaka K, Guo D, Masui K, Li B, Zhu S, Gu Y, Villa GR, Akhavan D, Nathanson D, Gini B, Mareninov S, Li R, Camacho CE, et al. EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metabolism. 17: 1000-8. PMID 23707073 DOI: 10.1016/J.Cmet.2013.04.013 |
0.672 |
|
2013 |
Masui K, Gini B, Wykosky J, Zanca C, Mischel PS, Furnari FB, Cavenee WK. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis. 34: 725-38. PMID 23455378 DOI: 10.1093/Carcin/Bgt086 |
0.666 |
|
2013 |
Iwanami A, Gini B, Zanca C, Matsutani T, Assuncao A, Nael A, Dang J, Yang H, Zhu S, Kohyama J, Kitabayashi I, Cavenee WK, Cloughesy TF, Furnari FB, Nakamura M, et al. PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proceedings of the National Academy of Sciences of the United States of America. 110: 4339-44. PMID 23440206 DOI: 10.1073/Pnas.1217602110 |
0.743 |
|
2012 |
Chaumeil MM, Gini B, Yang H, Iwanami A, Sukumar S, Ozawa T, Pieper RO, Mischel PS, James CD, Berger MS, Ronen SM. Longitudinal evaluation of MPIO-labeled stem cell biodistribution in glioblastoma using high resolution and contrast-enhanced MR imaging at 14.1 tesla. Neuro-Oncology. 14: 1050-61. PMID 22670012 DOI: 10.1093/Neuonc/Nos126 |
0.537 |
|
2012 |
Babic I, Gini B, Tanaka K, Jacobs C, Yong WH, Cloughesy TF, Mischel PS. Abstract 4321: EGFR signaling in glioblastoma regulates the expression of a brain specific isoform ofalphaPIX/Arhgef6to promote invasion Cancer Research. 72: 4321-4321. DOI: 10.1158/1538-7445.Am2012-4321 |
0.419 |
|
2012 |
Gini B, Guo D, Nathanson D, Shackelford D, Zhu S, Yang H, Tanaka K, Babic I, Akhavan D, Bonetti B, Mortensen D, Xu S, Raymon H, Chopra R, Mischel P. Abstract 1923: The mTOR kinase inhibitor, CC214, preferentially blocks the growth of EGFRvIII-activated glioblastomas Cancer Research. 72: 1923-1923. DOI: 10.1158/1538-7445.Am2012-1923 |
0.67 |
|
2011 |
Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh A, et al. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discovery. 1: 524-38. PMID 22145100 DOI: 10.1158/2159-8290.Cd-11-0124 |
0.664 |
|
2011 |
Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, et al. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discovery. 1: 442-56. PMID 22059152 DOI: 10.1158/2159-8290.Cd-11-0102 |
0.656 |
|
Show low-probability matches. |